Screener
Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
| Interest income | 7,104 | 8,227 | 15,347 | 17,597 |
| Interest expense | (7,940) | (3,264) | (15,759) | (6,561) |
| Other expense, net | (795) | (42) | (2,887) | (42) |
| Net loss | $(57,939) | $(42,281) | $(152,330) | $(115,519) |
| Net loss per common, Series A preferred and Series B preferred share: | ||||
| Basic and diluted net loss per common, Series A preferred, and Series B preferred share | $(1.99) | $(1.50) | $(5.24) | $(4.10) |
| Basic and diluted weighted average number of shares outstanding (Note 13) | 29,145,271 | 28,232,604 | 29,089,148 | 28,159,333 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s business segments — net loss?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — net loss of -$57.94M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s business segments — net loss decreased by 37.0% year-over-year, from -$42.28M to -$57.94M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s business segments — net loss?
- Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s business segments — net loss has grown at a -12.2% compound annual growth rate (CAGR), from -$373.63M to -$288.28M.
- What does business segments — net loss mean?
- This represents the bottom-line financial result for the segment after all operating expenses are deducted from revenue. For clinical-stage companies, this typically reflects the heavy investment in R&D relative to commercial income.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude